/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.
StockNews.com cut shares of Immunic (NASDAQ:IMUX – Free Report) from a hold rating to a sell rating in a research note published on Saturday morning. Separately, Brookline Capital Management reaffirmed a buy rating and set a $10.00 target price on shares of Immunic in a research report on Friday, April 5th. View Our Latest Report […]
Immunic (NASDAQ:IMUX – Get Free Report) will be announcing its earnings results before the market opens on Thursday, February 22nd. Analysts expect the company to announce earnings of ($0.51) per share for the quarter. Immunic (NASDAQ:IMUX – Get Free Report) last released its earnings results on Tuesday, November 14th. The company reported ($0.51) EPS for […]
Immunic, Inc. (NASDAQ:IMUX – Free Report) – Analysts at Leerink Partnrs issued their FY2028 earnings per share estimates for shares of Immunic in a research report issued to clients and investors on Monday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.66) per share for the year. The consensus estimate […]